WHO vaccine-preventable diseases: monitoring system. 2014 global summary

Last updated 05-Dec-2014 (Data received as of 1-Dec-2014)
Next overall update June 2015
EPI mother and child logo         
Select a country

Development status: Developed economy GNI / capita (US$): 39'1101 Infant (under 12 months) mortality rate: 42
GDP / capita (US$): 36'2091 Child (under 5 years) mortality rate: 52

Population data in thousands3

  2013  2012  2011  2010  2009  2000  1990  1980 
Total population 63'136  62'783  62'427  62'066  61'701  58'951  57'214  56'303 
Births 770  771  772  771  768  695  777  692 
Surviving infants 767  768  768  768  764  692  771  683 
Pop. less than 5 years 3'969  4'028  4'017  3'899  3'826  3'543  3'826  3'409 
Pop. less than 15 years 11'107  11'078  11'021  10'899  10'867  11'198  10'885  11'829 
Female 15-49 years 14'566  14'610  14'649  14'691  14'695  14'189  14'154  13'171 

Number of reported case

(Click for retrospective incidence data for United Kingdom of Great Britain and Northern Ireland (the))
Diphtheria
Japanese encephalitis
Measles 1'919  2'092  1'112  443  1'212  104  28'228  147'962 
Mumps 4'718  3'178  2'716  4'527  8'670  1'089 
Pertussis 6'090  11'980  1'243  518  846  866  16'605  22'924 
Polio*
Rubella 13  70  31  22  75 
Rubella (CRS)
Tetanus (neonatal)
Tetanus (total) 18  30 
Yellow fever
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for United Kingdom of Great Britain and Northern Ireland (the))
Vaccine year result method % card seen                                                
BCG         
DTP1         
DTP3          96  97  95  94  93  91  85 
HepB_BD         
HepB3         
Hib3          48  97  95  94  93  91 
JapEnc         
MCV          95  93  90  89  86  88  89 
MCV2          91  87  88  87  79  76 
PCV1          92 
PCV3          95  90  89  91 
Pol3          96  97  95  94  93  91  90 
Rota1         
Rota_last         
Rubella1          95  92  90  93  86 
TT2plus         
PAB         
VAD1         
YFV         
  ° indicates that more than 1 survey occurred that year

  Next update: July 2015

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for United Kingdom of Great Britain and Northern Ireland (the))
DTP1 98  99  98  98  97  97  94  66 
DTP3 96  97  95  94  93  91  84  41 
HepB3
HepB_BD
Hib3 97  97  95  94  93  91 
MCV 95  93  90  89  86  88  87  53 
MCV2 91  87  88  87  79  76 
PnC3 95  95  90  89 
Pol3 96  97  95  94  93  91  92  81 
Rota_last

Number of districts in the country 176  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
100 
   
/
|
|
\
Greater or equal to 90% 94
From 80 to 89% 5
From 50 to 79% 1
Less than 50% 0
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2013 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; No High risk areas and/or high risk groups
DTaPHibIPV 2, 3, 4 months; Yes
DTaPIPV 3-5 years; Yes
HPV 12-13 years; +1, +4-6 months; Yes
HepB birth; 1, 2, 3 months; Yes High risk
HibMenC 13 months; Yes
Influenza 2-3 years; >=65 years; Yes and risk groups
MMR 12-13 months; 3-5 years; Yes
MenACWY Issued for use in specific groups (e.g. asplenics)
MenC_conj 3 months; 14-18 years; Yes
Pneumo_conj 2, 4, 12 months; Yes
Pneumo_ps >=65 years; Yes At risk groups from 2 years
Rotavirus 2, 3 months;
TdIPV 13-18 years; Yes
Varicella 1st contact; Non-immune HCW

Immunizaton indicators

Indicator Expected answer 2013  2012  2011  2010  2009  2008  2007 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number              
Nº of districts with microplans that include activities to raise immunization coverage number 151  152  151  151  152  173  173 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR Yes  Yes  Yes  Yes       

System performance

Total Nº districts in country number 176  176  421  177  173  173  173 
Nº districts with DTP3 coverage >=80% number 175  176  176    166  86  30 
% of districts with DTP3 coverage >=80% From 0 to 100% 99  100  42    96  50  17 
Nº districts with measles (MCV1) coverage >=95% number 67  33   
% of districts with MCV1 coverage >=95% From 0 to 100% 38  19   

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND Yes             
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes        Yes  Yes  Yes 

Finance

Estimated percentage of routine vaccines funded by Government From 0 to 100%             100 

Sources

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2013, data for 2012
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.